<!DOCTYPE html>
<html>
<head>
<title>Ogivri, INN-trastuzumab</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge">
</head>
<body>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:266pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:274pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ANNEX I </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:297pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:175pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">SUMMARY OF PRODUCT CHARACTERISTICS </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:74pt;left:86pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This medicinal product is subject to additional monitoring. This will allow quick identification of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:87pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">new safety information. Healthcare professionals are asked to report any suspected adverse reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">See section 4.8 for how to report adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:112pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri 150 mg powder for concentrate for solution for infusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri 420 mg powder for concentrate for solution for infusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri 150 mg powder for concentrate for solution for infusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One vial contains 150 mg of trastuzumab, a humanised IgG1 monoclonal antibody produced by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity and ion exchange </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chromatography including specific viral inactivation and removal procedures. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri 420 mg powder for concentrate for solution for infusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One vial contains 420 mg of trastuzumab, a humanised IgG1 monoclonal antibody produced by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity and ion exchange </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chromatography including specific viral inactivation and removal procedures. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The reconstituted Ogivri solution contains 21 mg/mL of trastuzumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Excipient with known effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each 150 mg vial contains 115.2 mg sorbitol (E420).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each 420 mg vial contains 322.6 mg sorbitol (E420).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Powder for concentrate for solution for infusion (powder for concentrate). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">White to pale yellow lyophilised powder. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CLINICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast cancer </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Metastatic breast cancer </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(MBC): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as monotherapy for the treatment of those patients who have received at least two chemotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:757pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regimens for their metastatic disease. Prior chemotherapy must have included at least an </span></p>
<img style="position:absolute;top:70pt;left:70pt;width:15pt;height:13pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAADAAAAAqCAYAAAD1T9h6AAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAARUlEQVR4nO3PAQ0AIAAEobd/aI1xc4MGnG13HzsTaAnUBGoCNYGa
QE2gJlATqAnUBGoCNYGaQE2gJlATqAnUBGoCte8DD2cqKgG1q7tIAAAAAElFTkSu
QmCC">
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">positive patients must also have failed hormonal therapy, unless patients are unsuitable for these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatments </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in combination with paclitaxel for the treatment of those patients who have not received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chemotherapy for their metastatic disease and for whom an anthracycline is not suitable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in combination with docetaxel for the treatment of those patients who have not received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chemotherapy for their metastatic disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in combination with an aromatase inhibitor for the treatment of postmenopausal patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hormone-receptor positive MBC, not previously treated with trastuzumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Early breast cancer </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 5.1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paclitaxel or docetaxel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in combination with neoadjuvant chemotherapy followed by adjuvant Ogivri therapy, for locally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">advanced (including inflammatory) disease or tumours &gt; 2 cm in diameter (see sections 4.4 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri should only be used in patients with metastatic or EBC whose tumours have either HER2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">overexpression or HER2 gene amplification as determined by an accurate and validated assay (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sections 4.4 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Metastatic gastric cancer </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">junction who have not received prior anti-cancer treatment for their metastatic disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri should only be used in patients with metastatic gastric cancer (MGC) whose tumours have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">result. Accurate and validated assay methods should be used (see sections 4.4 and 5.1).</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HER2 testing is mandatory prior to initiation of therapy (see sections 4.4 and 5.1). Trastuzumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment should only be initiated by a physician experienced in the administration of cytotoxic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chemotherapy (see section 4.4), and should be administered by a healthcare professional only. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri intravenous formulation is not intended for subcutaneous administration and should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered via an intravenous infusion only. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If an alternate route of administration is required, other trastuzumab products offering such an option </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be used. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to prevent medication errors it is important to check the vial labels to ensure that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medicinal product being prepared and administered is Ogivri (trastuzumab) and not another </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab-containing product (e.g. trastuzumab emtansine or trastuzumab deruxtecan). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Metastatic breast cancer </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Three-weekly schedule </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended initial loading dose is 8 mg/kg body weight. The recommended maintenance dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at three-weekly intervals is 6 mg/kg body weight, beginning three weeks after the loading dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Weekly schedule </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended initial loading dose of trastuzumab is 4 mg/kg body weight. The recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly maintenance dose of trastuzumab is 2 mg/kg body weight, beginning one week after the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">loading dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Administration in combination with paclitaxel or docetaxel </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal trials (H0648g, M77001), paclitaxel or docetaxel was administered the day following the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">first dose of trastuzumab (for dose, see the Summary of Product Characteristics (SmPC) for paclitaxel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or docetaxel) and immediately after the subsequent doses of trastuzumab if the preceding dose of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab was well tolerated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Administration in combination with an aromatase inhibitor </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal trial (BO16216) trastuzumab and anastrozole were administered from day 1. There were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">no restrictions on the relative timing of trastuzumab and anastrozole at administration (for dose, see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the SmPC for anastrozole or other aromatase inhibitors). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Early breast cancer </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Three-weekly and weekly schedule </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">As a three-weekly regimen the recommended initial loading dose of trastuzumab is 8 mg/kg body </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weight. The recommended maintenance dose of trastuzumab at three-weekly intervals is 6 mg/kg body </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weight, beginning three weeks after the loading dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">As a weekly regimen (initial loading dose of 4 mg/kg followed by 2 mg/kg every week) concomitantly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with paclitaxel following chemotherapy with doxorubicin and cyclophosphamide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">See section 5.1 for chemotherapy combination dosing. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Metastatic gastric cancer </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Three-weekly schedule </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended initial loading dose is 8 mg/kg body weight. The recommended maintenance dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at three-weekly intervals is 6 mg/kg body weight, beginning three weeks after the loading dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast cancer and gastric cancer </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Duration of treatment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with MBC or MGC should be treated with trastuzumab until progression of disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with EBC should be treated with trastuzumab for 1 year or until disease recurrence, whichever </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurs first; extending treatment in EBC beyond one year is not recommended (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Dose reduction </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No reductions in the dose of trastuzumab were made during clinical trials. Patients may continue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy during periods of reversible, chemotherapy-induced myelosuppression but they should be </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monitored carefully for complications of neutropenia during this time. Refer to the SmPC for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paclitaxel, docetaxel or aromatase inhibitor for information on dose reduction or delays. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If left ventricular ejection fraction (LVEF) percentage drops &#x2265; 10 points from baseline AND to below </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 %, treatment should be suspended and a repeat LVEF assessment performed within approximately </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 weeks. If LVEF has not improved, or has declined further, or if symptomatic congestive heart failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(CHF) has developed, discontinuation of trastuzumab should be strongly considered, unless the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benefits for the individual patient are deemed to outweigh the risks. All such patients should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">referred for assessment by a cardiologist and followed up.</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Missed doses </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If the patient has missed a dose of trastuzumab by one week or less, then the usual maintenance dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(weekly regimen: 2 mg/kg; three-weekly regimen: 6 mg/kg) should be administered as soon as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">possible. Do not wait until the next planned cycle. Subsequent maintenance doses should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered 7 days or 21 days later according to the weekly or three-weekly schedules, respectively. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If the patient has missed a dose of trastuzumab by more than one week, a re-loading dose of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab should be administered over approximately 90 minutes (weekly regimen: 4 mg/kg; three-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly regimen: 8 mg/kg) as soon as possible. Subsequent trastuzumab maintenance doses (weekly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regimen: 2 mg/kg; three-weekly regimen 6 mg/kg respectively) should be administered 7 days or 21 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">days later according to the weekly or three-weekly schedules respectively.</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special populations </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dedicated pharmacokinetic studies in the elderly and those with renal or hepatic impairment have not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been carried out. In a population pharmacokinetic analysis, age and renal impairment were not shown </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to affect trastuzumab disposition. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of trastuzumab in the paediatric population. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Method of administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab loading dose should be administered as a 90-minute intravenous infusion. Do not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administer as an intravenous push or bolus. Trastuzumab intravenous infusion should be administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">by a healthcare provider prepared to manage anaphylaxis and an emergency kit should be available. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be observed for at least six hours after the start of the first infusion and for two hours </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">after the start of the subsequent infusions for symptoms like fever and chills or other infusion-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms (see sections 4.4 and 4.8). Interruption or slowing the rate of the infusion may help control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">such symptoms. The infusion may be resumed when symptoms abate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If the initial loading dose was well tolerated, the subsequent doses can be administered as a 30-minute </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infusion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For instructions on reconstitution of the medicinal product before administration, see section 6.6. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity to the active substance, murine proteins, or to any of the excipients listed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#x2022;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Severe dyspnoea at rest due to complications of advanced malignancy or requiring </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">supplementary oxygen therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Traceability </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to improve the traceability of biological medicinal products, the name and the batch number </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the administered product should be clearly recorded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HER2 testing must be performed in a specialised laboratory which can ensure adequate validation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the testing procedures (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Currently no data from clinical trials are available on re-treatment of patients with previous exposure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to trastuzumab in the adjuvant setting</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac dysfunction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">General considerations </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients treated with trastuzumab are at increased risk for developing CHF (New York Heart </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Association [NYHA] Class II-IV) or asymptomatic cardiac dysfunction. These events have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed in patients receiving trastuzumab therapy alone or in combination with paclitaxel or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">docetaxel, particularly following anthracycline (doxorubicin or epirubicin) containing chemotherapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These may be moderate to severe and have been associated with death (see section 4.8). In addition, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">caution should be exercised in treating patients with increased cardiac risk, e.g. hypertension, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">documented coronary artery disease, CHF, LVEF of &lt; 55%, older age. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All candidates for treatment with trastuzumab, but especially those with prior anthracycline and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cyclophosphamide (AC) exposure, should undergo baseline cardiac assessment including history and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physical examination, electrocardiogram (ECG), echocardiogram, and/or multigated acquisition </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(MUGA) scan or magnetic resonance imaging. Monitoring may help to identify patients who develop </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cardiac dysfunction. Cardiac assessments, as performed at baseline, should be repeated every 3 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during treatment and every 6 months following discontinuation of treatment until 24 months from the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">last administration of trastuzumab. A careful risk-benefit assessment should be made before deciding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to treat with trastuzumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab may persist in the circulation for up to 7 months after stopping Ogivri treatment based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">population pharmacokinetic analysis of all available data (see section 5.2). Patients who receive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anthracyclines after stopping trastuzumab may possibly be at increased risk of cardiac dysfunction. If </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab. If anthracyclines are used, the patient&#x2019;s cardiac function should be monitored carefully. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Formal cardiological assessment should be considered in patients in whom there are cardiovascular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concerns following baseline screening. In all patients cardiac function should be monitored during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment (e.g. every 12 weeks). Monitoring may help to identify patients who develop cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dysfunction. Patients who develop asymptomatic cardiac dysfunction may benefit from more frequent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monitoring (e.g. every 6 - 8 weeks). If patients have a continued decrease in left ventricular function, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">but remain asymptomatic, the physician should consider discontinuing therapy if no clinical benefit of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab therapy has been seen. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety of continuation or resumption of trastuzumab in patients who experience cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dysfunction has not been prospectively studied. If LVEF percentage drops &#x2265; 10 points from baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">AND to below 50%, treatment should be suspended and a repeat LVEF assessment performed within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 3 weeks. If LVEF has not improved, or declined further, or symptomatic CHF has </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">developed, discontinuation of trastuzumab should be strongly considered, unless the benefits for the </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">individual patient are deemed to outweigh the risks. All such patients should be referred for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessment by a cardiologist and followed up. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If symptomatic cardiac failure develops during trastuzumab therapy, it should be treated with standard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medicinal products for CHF. Most patients who developed CHF or asymptomatic cardiac dysfunction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in pivotal trials improved with standard CHF treatment consisting of an angiotensin-converting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) and a beta-blocker. The majority of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with cardiac symptoms and evidence of a clinical benefit of trastuzumab treatment continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on therapy without additional clinical cardiac events. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Metastatic breast cancer </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab and anthracyclines should not be given concurrently in combination in the MBC setting. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with MBC who have previously received anthracyclines are also at risk of cardiac dysfunction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:266pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with trastuzumab treatment, although the risk is lower than with concurrent use of trastuzumab and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anthracyclines. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Early breast cancer </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For patients with EBC, cardiac assessments, as performed at baseline, should be repeated every 3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">months during treatment and every 6 months following discontinuation of treatment until 24 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from the last administration of trastuzumab. In patients who receive anthracycline-containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chemotherapy further monitoring is recommended, and should occur yearly up to 5 years from the last </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration of trastuzumab, or longer if a continuous decrease of LVEF is observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with history of myocardial infarction (MI), angina pectoris requiring medical treatment, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">history of or existing CHF (NYHA Class II &#x2013;IV), LVEF of &lt; 55%, other cardiomyopathy, cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arrhythmia requiring medical treatment, clinically significant cardiac valvular disease, poorly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">controlled hypertension (hypertension controlled by standard medical treatment eligible), and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hemodynamic effective pericardial effusion were excluded from adjuvant and neoadjuvant EBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pivotal trials with trastuzumab and therefore treatment cannot be recommended in such patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adjuvant treatment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab and anthracyclines should not be given concurrently in combination in the adjuvant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment setting. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with EBC an increase in the incidence of symptomatic and asymptomatic cardiac events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was observed when trastuzumab was administered after anthracycline-containing chemotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared to administration with a non-anthracycline regimen of docetaxel and carboplatin and was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more marked when trastuzumab was administered concurrently with taxanes than when administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sequentially to taxanes. Regardless of the regimen used, most symptomatic cardiac events occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within the first 18 months. In one of the 3 pivotal studies conducted in which a median follow-up of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5 years was available (BCIRG006) a continuous increase in the cumulative rate of symptomatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cardiac or LVEF events was observed in patients who were administered trastuzumab concurrently </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with a taxane following anthracycline therapy up to 2.37 % compared to approximately 1 % in the two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparator arms (anthracycline plus cyclophosphamide followed by taxane and taxane, carboplatin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and trastuzumab). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Risk factors for a cardiac event identified in four large adjuvant studies included advanced age </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&gt; 50 years), low LVEF (&lt; 55 %) at baseline, prior to or following the initiation of paclitaxel </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment, decline in LVEF by 10-15 points, and prior or concurrent use of anti-hypertensive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medicinal products. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients receiving trastuzumab after completion of adjuvant chemotherapy, the risk of cardiac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dysfunction was associated with a higher cumulative dose of anthracycline given prior to initiation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab and a body mass index (BMI) &gt; 25 kg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Neoadjuvant-adjuvant treatment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with EBC eligible for neoadjuvant-adjuvant treatment, trastuzumab should be used </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concurrently with anthracyclines only in chemotherapy-naive patients and only with low-dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anthracycline regimens i.e. maximum cumulative doses of doxorubicin 180 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or epirubicin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">360 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If patients have been treated concurrently with a full course of low-dose anthracyclines and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab in the neoadjuvant setting, no additional cytotoxic chemotherapy should be given after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:266pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">surgery. In other situations, the decision on the need for additional cytotoxic chemotherapy is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">determined based on individual factors. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Experience of concurrent administration of trastuzumab with low dose anthracycline regimens is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">currently limited to the trial MO16432. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal trial MO16432, trastuzumab was administered concurrently with neoadjuvant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chemotherapy containing three cycles of doxorubicin (cumulative dose 180 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The incidence of symptomatic cardiac dysfunction was 1.7 % in the trastuzumab arm. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical experience is limited in patients above 65 years of age. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infusion-related reactions (IRRs) and hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious IRRs to trastuzumab infusion including dyspnoea, hypotension, wheezing, hypertension, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bronchospasm, supraventricular tachyarrhythmia, reduced oxygen saturation, anaphylaxis, respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">distress, urticaria and angioedema have been reported (see section 4.8). Pre-medication may be used to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reduce risk of occurrence of these events. The majority of these events occur during or within 2.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hours of the start of the first infusion. Should an infusion reaction occur the infusion should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinued or the rate of infusion slowed and the patient should be monitored until resolution of all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed symptoms (see section 4.2). These symptoms can be treated with an analgesic/antipyretic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">such as meperidine or paracetamol, or an antihistamine such as diphenhydramine. The majority of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients experienced resolution of symptoms and subsequently received further infusions of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab. Serious reactions have been treated successfully with supportive therapy such as oxygen, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">beta agonists, and corticosteroids. In rare cases, these reactions are associated with a clinical course </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">culminating in a fatal outcome. Patients experiencing dyspnoea at rest due to complications of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">advanced malignancy and comorbidities may be at increased risk of a fatal infusion reaction. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Therefore, these patients should not be treated with trastuzumab (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Initial improvement followed by clinical deterioration and delayed reactions with rapid clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">deterioration have also been reported. Fatalities have occurred within hours and up to one week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following infusion. On very rare occasions, patients have experienced the onset of infusion symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and pulmonary symptoms more than six hours after the start of the trastuzumab infusion. Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be warned of the possibility of such a late onset and should be instructed to contact their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physician if these symptoms occur. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Severe pulmonary events have been reported with the use of trastuzumab in the post-marketing setting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 4.8). These events have occasionally been fatal. In addition, cases of interstitial lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease including lung infiltrates, acute respiratory distress syndrome, pneumonia, pneumonitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pleural effusion, respiratory distress, acute pulmonary oedema and respiratory insufficiency have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reported. Risk factors associated with interstitial lung disease include prior or concomitant therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with other anti-neoplastic therapies known to be associated with it such as taxanes, gemcitabine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vinorelbine and radiation therapy. These events may occur as part of an infusion-related reaction or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with a delayed onset. Patients experiencing dyspnoea at rest due to complications of advanced </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignancy and comorbidities may be at increased risk of pulmonary events. Therefore, these patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should not be treated with trastuzumab (see section 4.3). Caution should be exercised for pneumonitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">especially in patients being treated concomitantly with taxanes. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Excipients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Sorbitol content </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri 150 mg contains 115.2 mg sorbitol in each vial.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri 420 mg contains 322.6 mg sorbitol in each vial. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with hereditary fructose intolerance (HFI) must not be given this medicine unless strictly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A detailed history with regards to HFI symptoms has to be taken of each patient prior to being given </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this medicinal product. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Sodium </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say, essentially </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2018;sodium-free&#x2019;. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No interaction studies have been performed. Clinically significant interactions between trastuzumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and the concomitant medicinal products used in clinical trials have not been observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Effect of trastuzumab on the pharmacokinetics of other antineoplastic agents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacokinetic data from studies BO15935 and M77004 in women with HER2-positive MBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">suggested that exposure to paclitaxel and doxorubicin (and their major metabolites 6-</span><tt><span style="font-family:MS Mincho,monospace;font-size:11.04pt">&#x3b1;</span></tt><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> hydroxyl-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab (8 mg/kg or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 mg/kg intravenous loading dose followed by 6 mg/kg q3w or 2 mg/kg q1w intravenous, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">However, trastuzumab may elevate the overall exposure of one doxorubicin metabolite, (7-deoxy-13 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dihydro-doxorubicinone, D7D). The bioactivity of D7D and the clinical impact of the elevation of this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">metabolite were unclear. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Data from study JP16003, a single-arm study of trastuzumab (4 mg/kg intravenous loading dose and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 mg/kg intravenous weekly) and docetaxel (60 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> intravenous) in Japanese women with HER2- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">positive MBC, suggested that concomitant administration of trastuzumab had no effect on the single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose pharmacokinetics of docetaxel. Study JP19959 was a sub study of BO18255 (ToGA) performed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in male and female Japanese patients with advanced gastric cancer (AGC) to study the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pharmacokinetics of capecitabine and cisplatin when used with or without trastuzumab. The results of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this sub study suggested that the exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not affected by concurrent use of cisplatin or by concurrent use of cisplatin plus trastuzumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">However, capecitabine itself showed higher concentrations and a longer half-life when combined with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab. The data also suggested that the pharmacokinetics of cisplatin were not affected by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concurrent use of capecitabine or by concurrent use of capecitabine plus trastuzumab. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacokinetic data from Study H4613g/GO01305 in patients with metastatic or locally advanced </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inoperable HER2-positive cancer suggested that trastuzumab had no impact on the PK of carboplatin. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Effect of antineoplastic agents on trastuzumab pharmacokinetics  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">By comparison of simulated serum trastuzumab concentrations after trastuzumab monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(4 mg/kg loading/2 mg/kg q1w intravenous) and observed serum concentrations in Japanese women </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with HER2- positive MBC (study JP16003) no evidence of a PK effect of concurrent administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">docetaxel on the pharmacokinetics of trastuzumab was found. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Comparison of PK results from two phase II studies (BO15935 and M77004) and one phase III study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(H0648g) in which patients were treated concomitantly with trastuzumab and paclitaxel and two phase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">II studies in which trastuzumab was administered as monotherapy (W016229 and MO16982), in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">women with HER2-positive MBC indicates that individual and mean trastuzumab trough serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations varied within and across studies but there was no clear effect of the concomitant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration of paclitaxel on the pharmacokinetics of trastuzumab. Comparison of trastuzumab PK </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data from Study M77004 in which women with HER2-positive MBC were treated concomitantly with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab, paclitaxel and doxorubicin to trastuzumab PK data in studies where trastuzumab was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered as monotherapy (H0649g) or in combination with anthracycline plus cyclophosphamide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or paclitaxel (Study H0648g), suggested no effect of doxorubicin and paclitaxel on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pharmacokinetics of trastuzumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacokinetic data from Study H4613g/GO01305 suggested that carboplatin had no impact on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PK of trastuzumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The administration of concomitant anastrozole did not appear to influence the pharmacokinetics of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fertility, pregnancy and lactation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential should be advised to use effective contraception during treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with trastuzumab and for 7 months after treatment has concluded (see section 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reproduction studies have been conducted in Cynomolgus monkeys at doses up to 25 times that of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly human maintenance dose of 2 mg/kg trastuzumab intravenous formulation and have revealed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">no evidence of impaired fertility or harm to the foetus. Placental transfer of trastuzumab during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">early (days 20&#x2013;50 of gestation) and late (days 120&#x2013;150 of gestation) foetal development period was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed. It is not known whether trastuzumab can affect reproductive capacity. As animal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reproduction studies are not always predictive of human response, trastuzumab should be avoided </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during pregnancy unless the potential benefit for the mother outweighs the potential risk to the foetus. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the post-marketing setting, cases of foetal renal growth and/or function impairment in association </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with oligohydramnios, some associated with fatal pulmonary hypoplasia of the foetus, have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reported in pregnant women receiving trastuzumab. Women who become pregnant should be advised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the possibility of harm to the foetus. If a pregnant woman is treated with trastuzumab, or if a patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">becomes pregnant while receiving trastuzumab or within 7 months following the last dose of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab, close monitoring by a multidisciplinary team is desirable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">11 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A study conducted in Cynomolgus monkeys at doses 25 times that of the weekly human maintenance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of 2 mg/kg trastuzumab intravenous formulation from days 120 to 150 of pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demonstrated that trastuzumab is secreted in the milk postpartum. The exposure to trastuzumab in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">utero and presence of trastuzumab in the serum of infant monkeys was not associated with any adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">effects on their growth or development from birth to 1 month of age. It is not known whether </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab is secreted in human milk. As human IgG1 is secreted into human milk, and the potential </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for harm to the infant is unknown, women should not breast-feed during trastuzumab therapy and for 7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">months after the last dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no fertility data available. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri has a minor influence on the ability to drive and use machines (see section 4.8). Dizziness and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">somnolence may occur during treatment with Ogivri (see section 4.8). Patients experiencing infusion-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">related symptoms (see section 4.4) should be advised not to drive and use machines until symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">abate.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Summary of the safety profile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Amongst the most serious and/or common adverse reactions reported in trastuzumab usage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(intravenous and subcutaneous formulations) to date are cardiac dysfunction, infusion-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions, haematotoxicity (in particular neutropenia), infections and pulmonary adverse reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tabulated list of adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In this section, the following categories of frequency have been used: very common (&#x2265; 1/10), common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#x2265; 1/100 to &lt; 1/10), uncommon (&#x2265; 1/1,000 to &lt; 1/100), rare (&#x2265; 1/10,000 to &lt; 1/1,000), very rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&lt; 1/10,000), not known (cannot be estimated from the available data). Within each frequency </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">grouping, adverse reactions are presented in order of decreasing seriousness. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Presented in Table 1 are adverse reactions that have been reported in association with the use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intravenous trastuzumab alone or in combination with chemotherapy in pivotal clinical trials and in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">post-marketing setting. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All the terms included are based on the highest percentage seen in pivotal clinical trials. In addition, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">terms reported in the post marketing setting are included in Table 1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 1 Undesirable effects reported with intravenous trastuzumab monotherapy or in combination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with chemotherapy in pivotal clinical trials (N = 8386) and in post-marketing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System organ class</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:211pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse reaction</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:411pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections and infestations</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infection</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nasopharyngitis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neutropenic sepsis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cystitis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Influenza</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sinusitis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Skin infection</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System organ class</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:211pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse reaction</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:411pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rhinitis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Upper respiratory tract infection</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Urinary tract infection</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharyngitis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neoplasms benign, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignant and unspecified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(incl. cysts and polyps)</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignant neoplasm progression</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neoplasm progression</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Blood and lymphatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">system disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Febrile neutropenia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Anaemia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neutropenia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">White blood cell count </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decreased/leukopenia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Thrombocytopenia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypoprothrombinaemia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immune thrombocytopenia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immune system disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Anaphylactic reaction</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Anaphylactic shock</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Metabolism and nutrition </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Weight decreased/Weight loss</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Anorexia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tumour lysis syndrome </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hyperkalaemia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psychiatric disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Insomnia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Anxiety</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Depression</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nervous system disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tremor</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dizziness</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Headache</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paraesthesia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dysgeusia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Peripheral neuropathy</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypertonia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Somnolence</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Eye disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Conjunctivitis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lacrimation increased</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dry eye</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Papilloedema</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Retinal haemorrhage</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ear and labyrinth disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Deafness</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1 </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Blood pressure decreased</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1 </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Blood pressure increased</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1 </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Heart beat irregular</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac flutter</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ejection fraction decreased*</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac failure (congestive)</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+1</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Supraventricular tachyarrhythmia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiomyopathy</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Palpitation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pericardial effusion</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiogenic shock</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Gallop rhythm present</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">13 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System organ class</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:211pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse reaction</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:411pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vascular disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hot flush</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+1 </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypotension</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vasodilatation</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory, thoracic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mediastinal disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dyspnoea</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cough</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Epistaxis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rhinorrhoea</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pneumonia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Asthma</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lung disorder</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pleural effusion</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+1</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Wheezing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:243pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pneumonitis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:243pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary fibrosis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory distress</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory failure</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lung infiltration</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Acute pulmonary oedema</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Acute respiratory distress syndrome</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Bronchospasm</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypoxia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Oxygen saturation decreased</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Laryngeal oedema</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Orthopnoea</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary oedema</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Interstitial lung disease</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Gastrointestinal disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Diarrhoea</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vomiting</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nausea</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1 </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lip swelling</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Abdominal pain</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dyspepsia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Constipation</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Stomatitis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Haemorrhoids</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dry mouth</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatobiliary disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatocellular injury</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Liver tenderness</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Jaundice</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Skin and subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tissue disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erythema</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rash</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1 </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Swelling face</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Alopecia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nail disorder</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Palmar-plantar erythrodysaesthesia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">syndrome </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Acne</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dry skin</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ecchymosis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hyperhydrosis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">14 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System organ class</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:211pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse reaction</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:411pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Maculopapular rash</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pruritus</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Onychoclasis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dermatitis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Urticaria</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Angioedema</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Musculoskeletal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">connective tissue disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Arthralgia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Muscle tightness</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Myalgia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Arthritis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Back pain</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Bone pain</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:244pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Muscle spasms</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:244pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neck Pain</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pain in extremity</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and urinary disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal disorder</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Glomerulonephritis membranous</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Glomerulonephropathy</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal failure</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy, puerperium and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">perinatal conditions</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Oligohydramnios</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal hypoplasia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary hypoplasia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reproductive system and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast disorders</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast inflammation/mastitis</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">General disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conditions</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Asthenia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Chest pain</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Chills</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fatigue</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Influenza-like symptoms</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infusion related reaction</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pain</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pyrexia</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mucosal inflammation</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Peripheral oedema</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malaise</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Oedema</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Injury, poisoning and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">procedural complications</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Contusion</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:6.48pt">+</span><span style="font-family:TimesNewRoman,serif;font-size:9.96pt"> Denotes adverse reactions that have been reported in association with a fatal outcome. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:6.48pt">1</span><span style="font-family:TimesNewRoman,serif;font-size:9.96pt"> Denotes adverse reactions that are reported largely in association with Infusion-related reactions. Specific </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">percentages for these are not available. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">* Observed with combination therapy following anthracyclines and combined with taxanes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Description of selected adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Cardiac dysfunction </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Congestive heart failure (NYHA Class II &#x2013; IV) is a common adverse reaction associated with the use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of trastuzumab and has been associated with a fatal outcome (see section 4.4). Signs and symptoms of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cardiac dysfunction such as dyspnoea, orthopnoea, increased cough, pulmonary oedema, S3 gallop, or </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">15 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reduced ventricular ejection fraction, have been observed in patients treated with trastuzumab (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In 3 pivotal clinical trials of adjuvant trastuzumab given in combination with chemotherapy, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">incidence of grade 3/4 cardiac dysfunction (specifically symptomatic Congestive Heart Failure) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">similar in patients who were administered chemotherapy alone (i.e. did not receive trastuzumab) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients who were administered trastuzumab sequentially after a taxane (0.3-0.4 %). The rate was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">highest in patients who were administered trastuzumab concurrently with a taxane (2.0 %). In the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neoadjuvant setting, the experience of concurrent administration of trastuzumab and low dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anthracycline regimen is limited (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">When trastuzumab was administered after completion of adjuvant chemotherapy NYHA Class III - IV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">heart failure was observed in 0.6 % of patients in the one-year arm after a median follow-up of 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">months. In study BO16348, after a median follow-up of 8 years the incidence of severe CHF (NYHA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Class III &amp; IV) in the trastuzumab 1 year treatment arm was 0.8 %, and the rate of mild symptomatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and asymptomatic left ventricular dysfunction was 4.6 %. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reversibility of severe CHF (defined as a sequence of at least two consecutive LVEF values &#x2265; 50 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">after the event) was evident for 71.4 % of trastuzumab-treated patients. Reversibility of mild </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptomatic and asymptomatic left ventricular dysfunction was demonstrated for 79.5 % of patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Approximately 17 % of cardiac dysfunction related events occurred after completion of trastuzumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal metastatic trials of intravenous trastuzumab, the incidence of cardiac dysfunction varied </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">between 9 % and 12 % when it was combined with paclitaxel compared with 1 % &#x2013; 4 % for paclitaxel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alone. For monotherapy, the rate was 6 % &#x2013; 9 %. The highest rate of cardiac dysfunction was seen in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving trastuzumab concurrently with anthracycline/cyclophosphamide (27 %), and was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly higher than for anthracycline/cyclophosphamide alone (7 % &#x2013; 10 %). In a subsequent trial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with prospective monitoring of cardiac function, the incidence of symptomatic CHF was 2.2 % in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving trastuzumab and docetaxel, compared with 0 % in patients receiving docetaxel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alone. Most of the patients (79 %) who developed cardiac dysfunction in these trials experienced an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement after receiving standard treatment for CHF. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Infusion reactions, allergic-like reactions and hypersensitivity </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is estimated that approximately 40 % of patients who are treated with trastuzumab will experience </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">some form of infusion-related reaction. However, the majority of infusion-related reactions are mild to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate in intensity (NCI-CTC grading system) and tend to occur earlier in treatment, i.e. during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infusions one, two and three and lessen in frequency in subsequent infusions. Reactions include chills, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fever, dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respiratory distress, rash, nausea, vomiting and headache (see section 4.4). The rate of infusion-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions of all grades varied between studies depending on the indication, the data collection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methodology, and whether trastuzumab was given concurrently with chemotherapy or as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Severe anaphylactic reactions requiring immediate additional intervention can occur usually during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">either the first or second infusion of trastuzumab (see section 4.4) and have been associated with a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fatal outcome. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Anaphylactoid reactions have been observed in isolated cases. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Haematotoxicity </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Febrile neutropenia, leukopenia, anaemia, thrombocytopenia and neutropenia occurred very </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">commonly. The frequency of occurrence of hypoprothrombinemia is not known. The risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neutropenia may be slightly increased when trastuzumab is administered with docetaxel following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anthracycline therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">16 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pulmonary events </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Severe pulmonary adverse reactions occur in association with the use of trastuzumab and have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">associated with a fatal outcome. These include, but are not limited to, pulmonary infiltrates, acute </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respiratory distress syndrome, pneumonia, pneumonitis, pleural effusion, respiratory distress, acute </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pulmonary oedema and respiratory insufficiency (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Details of risk minimisation measures that are consistent with the EU Risk Management Plan are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">presented in (section 4.4) Warnings and Precautions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunogenicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the neoadjuvant-adjuvant EBC study (BO22227), at a median follow-up exceeding 70 months, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10.1 % (30/296) of patients treated with trastuzumab intravenous developed antibodies against </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neutralizing anti-trastuzumab antibodies were detected in post-baseline samples in 2 of 30 patients in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the trastuzumab intravenous arm. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The clinical relevance of these antibodies is not known. The presence of anti-trastuzumab antibodies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had no impact on pharmacokinetics, efficacy (determined by pathological Complete Response [pCR] </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and event free survival [EFS]) and safety determined by occurrence of administration related reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(ARRs) of trastuzumab intravenous. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There are no immunogenicity data available for trastuzumab in gastric cancer. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Switching treatment between trastuzumab intravenous and trastuzumab subcutaneous formulation and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vice versa. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study MO22982 investigated switching between the trastuzumab intravenous and trastuzumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous formulation with a primary objective to evaluate patient preference for either </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intravenous or the subcutaneous route of trastuzumab administration. In this trial, 2 cohorts (one using </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous formulation in vial and one using subcutaneous formulation in administration system) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were investigated using a 2-arm, cross-over design with 488 patients being randomized to one of two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">different three-weekly Trastuzumab treatment sequences (intravenous [Cycles 1-4]&#x2192; subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">[Cycles 5-8], or subcutaneous [Cycles 1-4]&#x2192; intravenous [Cycles 5-8]). Patients were either na&#xef;ve to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab intravenous treatment (20.3 %) or pre-exposed to trastuzumab intravenous (79.7 %). For </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the sequence intravenous &#x2192; subcutaneous (subcutaneous vial and subcutaneous formulation in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration system cohorts combined), adverse event rates (all grades) were described pre-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">switching (Cycles 1-4) and post-switching (Cycles 5-8) as 53.8 % vs. 56.4 %, respectively; for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sequence subcutaneous &#x2192; intravenous (subcutaneous vial and subcutaneous formulation in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration system cohorts combined), adverse event rates (all grades) were described pre- and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">post-switching as 65.4 % vs. 48.7 %, respectively. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pre-switching rates (Cycles 1-4) for serious adverse events, grade 3 adverse events and treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinuations due to adverse events were low (&lt; 5 %) and similar to post-switching rates (Cycles 5-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8). No grade 4 or grade 5 adverse events were reported. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting of suspected adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">listed in </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">Appendix V</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">.</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#008000"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">17 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Overdose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no experience with overdose in human clinical trials. Single doses of trastuzumab alone </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">greater than 10 mg/kg have not been administered in the clinical trials; a maintenance dose of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 mg/kg q3w following a loading dose of 8 mg/kg has been studied in a clinical trial with metastatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">gastric cancer patients. Doses up to this level were well tolerated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.1  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacodynamic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC03 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri is a biosimilar medicinal product. Detailed information is available on the website of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">European Medicines Agency </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu.</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab is a recombinant humanised IgG1 monoclonal antibody against the human epidermal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">growth factor receptor 2 (HER2). Overexpression of HER2 is observed in 20 %-30 % of primary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast cancers. Studies of HER2-positivity rates in gastric cancer (GC) using immunohistochemistry </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(IHC) and fluorescence </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in situ </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hybridization (FISH) or chromogenic </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in situ </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hybridization (CISH) have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">shown that there is a broad variation of HER2-positivity ranging from 6.8 % to 34.0 % for IHC and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7.1 % to 42.6 % for FISH. Studies indicate that breast cancer patients whose tumours overexpress </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HER2 have a shortened disease-free survival compared to patients whose tumours do not overexpress </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HER2. The extracellular domain of the receptor (ECD, p105) can be shed into the blood stream and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">measured in serum samples.</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mechanism of action </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab binds with high affinity and specificity to sub-domain IV, a juxta-membrane region of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HER2&#x2019;s extracellular domain. Binding of trastuzumab to HER2 inhibits ligand-independent HER2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">signalling and prevents the proteolytic cleavage of its extracellular domain, an activation mechanism </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of HER2. As a result, trastuzumab has been shown, in both </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assays and in animals, to inhibit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the proliferation of human tumour cells that overexpress HER2. Additionally, trastuzumab is a potent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mediator of antibody-dependent cell-mediated cytotoxicity (ADCC). </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, trastuzumab-mediated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with cancer cells that do not overexpress HER2. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detection of HER2 overexpression or HER2 gene amplification </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Detection of HER2 overexpression or HER2 gene amplification in breast cancer </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab should only be used in patients whose tumours have HER2 overexpression or HER2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">gene amplification as determined by an accurate and validated assay. HER2 overexpression should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">detected using an immunohistochemistry (IHC)-based assessment of fixed tumour blocks (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 4.4). HER2 gene amplification should be detected using fluorescence </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in situ </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hybridisation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(FISH) or chromogenic </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in situ </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hybridisation (CISH) of fixed tumour blocks. Patients are eligible for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri treatment if they show strong HER2 overexpression as described by a 3+ score by IHC or a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">positive FISH or CISH result. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">To ensure accurate and reproducible results, the testing must be performed in a specialised laboratory, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which can ensure validation of the testing procedures. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">18 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended scoring system to evaluate the IHC staining patterns is as stated in Table 2: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 2 Recommended scoring system to evaluate the IHC staining patterns in breast cancer </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:74pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Score</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:127pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Staining pattern</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:381pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HER2 overexpression </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:381pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">assessment</span></b><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No staining is observed or membrane staining is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed in &lt; 10 % of the tumour cells</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:381pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Negative</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1+</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A faint/barely perceptible membrane staining is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">detected in &gt; 10 % of the tumour cells. The cells are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">only stained in part of their membrane.</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:381pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Negative</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2+</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A weak to moderate complete membrane staining is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">detected in &gt; 10 % of the tumour cells.</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:381pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Equivocal</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3+</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Strong complete membrane staining is detected in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&gt; 10 % of the tumour cells.</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:381pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Positive</span><span style="font-family:TimesNewRoman,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, FISH is considered positive if the ratio of the HER2 gene copy number per tumour cell to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the chromosome 17 copy number is greater than or equal to 2, or if there are more than 4 copies of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HER2 gene per tumour cell if no chromosome 17 control is used. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, CISH is considered positive if there are more than 5 copies of the HER2 gene per nucleus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in greater than 50 % of tumour cells. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For full instructions on assay performance and interpretation please refer to the package inserts of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">validated FISH and CISH assays. Official recommendations on HER2 testing may also apply. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For any other method that may be used for the assessment of HER2 protein or gene expression, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">analyses should only be performed by laboratories that provide adequate state-of-the-art performance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of validated methods. Such methods must clearly be precise and accurate enough to demonstrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">overexpression of HER2 and must be able to distinguish between moderate (congruent with 2+) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">strong (congruent with 3+) overexpression of HER2. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Detection of HER2 over expression or HER2 gene amplification in gastric cancer </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Only an accurate and validated assay should be used to detect HER2 over expression or HER2 gene </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">amplification. IHC is recommended as the first testing modality and in cases where HER2 gene </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">amplification status is also required, either a silver-enhanced </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in situ </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hybridization (SISH) or a FISH </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">technique must be applied. SISH technology is however, recommended to allow for the parallel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evaluation of tumour histology and morphology. To ensure validation of testing procedures and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">generation of accurate and reproducible results, HER2 testing must be performed in a laboratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">staffed by trained personnel. Full instructions on assay performance and results interpretation should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">be taken from the product information leaflet provided with the HER2 testing assays used. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the ToGA (BO18255) trial, patients whose tumours were either IHC3+ or FISH positive were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as HER2 positive and thus included in the trial. Based on the clinical trial results, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">beneficial effects were limited to patients with the highest level of HER2 protein overexpression, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined by a 3+ score by IHC, or a 2+ score by IHC and a positive FISH result. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a method comparison study (study D008548) a high degree of concordance (&gt;95 %) was observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for SISH and FISH techniques for the detection of HER2 gene amplification in gastric cancer patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HER2 over expression should be detected using an immunohistochemistry (IHC)-based assessment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fixed tumour blocks; HER2 gene amplification should be detected using </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in situ </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hybridisation using </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">either SISH or FISH on fixed tumour blocks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">19 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended scoring system to evaluate the IHC staining patterns is as stated in Table 3: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 3 Recommended scoring system to evaluate the IHC staining patterns in gastric cancer </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Score</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:129pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Surgical specimen - staining </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:129pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">pattern</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:273pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Biopsy specimen &#x2013;</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:273pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">staining pattern</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:426pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HER2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:426pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">overexpression </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:426pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">assessment</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No reactivity or membranous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivity in &lt; 10 % of tumour </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cells </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No reactivity or membranous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivity in any tumour cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:426pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:426pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Negative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1+ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Faint &#x2044; barely perceptible </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">membranous reactivity in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 10 % of tumour cells; cells </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are reactive only in part of their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">membrane </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tumour cell cluster with a faint &#x2044; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">barely perceptible membranous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivity irrespective of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">percentage of tumour cells stained </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:426pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:426pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Negative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2+ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Weak to moderate complete, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">basolateral or lateral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">membranous reactivity in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 10 % of tumour cells </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tumour cell cluster with a weak </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to moderate complete, basolateral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or lateral membranous reactivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">irrespective of percentage of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tumour cells stained </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:426pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:426pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Equivocal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3+ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Strong complete, basolateral or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lateral membranous reactivity in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 10 % of tumour cells </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tumour cell cluster with a strong </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">complete, basolateral or lateral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">membranous reactivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">irrespective of percentage of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tumour cells stained </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:426pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:426pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Positive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, SISH or FISH is considered positive if the ratio of the HER2 gene copy number per tumour </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cell to the chromosome 17 copy number is greater than or equal to 2. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical efficacy and safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Metastatic breast cancer </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab has been used in clinical trials as monotherapy for patients with MBC who have tumours </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">that overexpress HER2 and who have failed one or more chemotherapy regimens for their metastatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease (trastuzumab alone). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab has also been used in combination with paclitaxel or docetaxel for the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who have not received chemotherapy for their metastatic disease. Patients who had previously </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received anthracycline-based adjuvant chemotherapy were treated with paclitaxel (175 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> infused </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">over 3 hours) with or without trastuzumab. In the pivotal trial of docetaxel (100 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> infused over </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 hour) with or without trastuzumab, 60 % of the patients had received prior anthracycline-based </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adjuvant chemotherapy. Patients were treated with trastuzumab until progression of disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of trastuzumab in combination with paclitaxel in patients who did not receive prior </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adjuvant anthracyclines has not been studied. However, trastuzumab plus docetaxel was efficacious in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients whether or not they had received prior adjuvant anthracyclines. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The test method for HER2 overexpression used to determine eligibility of patients in the pivotal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab monotherapy and trastuzumab plus paclitaxel clinical trials employed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunohistochemical staining for HER2 of fixed material from breast tumours using the murine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monoclonal antibodies CB11 and 4D5. These tissues were fixed in formalin or Bouin&#x2019;s fixative. This </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigative clinical trial assay performed in a central laboratory utilised a 0 to 3+ scale. Patients </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">classified as staining 2+ or 3+ were included, while those staining 0 or 1+ were excluded. Greater than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70 % of patients enrolled exhibited 3+ overexpression. The data suggest that beneficial effects were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">greater among those patients with higher levels of overexpression of HER2 (3+). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The main test method used to determine HER2 positivity in the pivotal trial of docetaxel, with or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">without trastuzumab, was immunohistochemistry. A minority of patients was tested using fluorescence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in-situ </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hybridisation (FISH). In this trial, 87 % of patients entered had disease that was IHC3+, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">95 % of patients entered had disease that was IHC3+ and/or FISH-positive. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Weekly dosing in metastatic breast cancer</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy results from the monotherapy and combination therapy studies are summarised in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 4:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 4 Efficacy results from the monotherapy and combination therapy studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Parameter</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:165pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Monotherapy</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Combination Therapy</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:167pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Trastuzumab</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">1</span></b></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:200pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:182pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 172</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:239pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Trastuzumab </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:261pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">plus </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:247pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">paclitaxel</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">2</span></b></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:256pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 68</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:308pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paclitaxel</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">2</span></b></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:318pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 77</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:361pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Trastuzumab </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:383pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">plus </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:370pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">docetaxel</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">3</span></b></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 92</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:431pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Docetaxel</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">3</span></b></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:455pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:440pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 94</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response rate</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(95 %CI)</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:181pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(13 - 25) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:260pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(36 - 61) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:322pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:317pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(9 - 27) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:382pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(50-71) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:444pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:439pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(25-45) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median duration of </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">response (months) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(95 %CI)</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:193pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:178pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(5.6-10.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:264pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(7.3-8.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:314pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(3.7-7.4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:384pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:393pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:368pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(9.3 &#x2013; 15.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:448pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:436pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(4.6-7.6) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median TTP </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(months) (95 %CI)</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:193pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:181pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(2.6-3.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:264pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:249pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(6.2-12.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:314pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(2.0-4.4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:384pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:371pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(9.2-13.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:448pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:436pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(5.4-7.2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median Survival</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(months) (95 %CI)</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:191pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(12.3-ne) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:262pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:246pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(18.6-33.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(11.2-23.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:384pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:369pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(27.3-40.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:443pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22.74 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:431pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(19.1-30.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">TTP = time to progression; &quot;ne&quot; indicates that it could not be estimated or it was not yet reached. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">1.       Study H0649g: IHC3+ patient subset </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">2.       Study H0648g: IHC3+ patient subset </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">3.       Study M77001: Full analysis set (intent-to-treat), 24 months results </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Combination treatment with Trastuzumab and anastrozole </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab has been studied in combination with anastrozole for first line treatment of MBC in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HER2 overexpressing, hormone-receptor (i.e. estrogen-receptor (ER) and/or progesterone-receptor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(PR)) positive postmenopausal patients. Progression free survival was doubled in the trastuzumab plus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anastrozole arm compared to anastrozole (4.8 months versus 2.4 months). For the other parameters the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvements seen for the combination were for overall response (16.5 % versus 6.7 %); clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benefit rate (42.7 % versus 27.9 %); time to progression (4.8 months versus 2.4 months). For time to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response and duration of response no difference could be recorded between the arms. The median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">overall survival was extended by 4.6 months for patients in the combination arm. The difference was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not statistically significant, however more than half of the patients in the anastrozole alone arm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">crossed over to a trastuzumab containing regimen after progression of disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">21 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Three -weekly dosing in metastatic breast cancer</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy results from the non-comparative monotherapy and combination therapy studies are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">summarised in Table 5: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 5 Efficacy results from the non-comparative monotherapy and combination therapy studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Parameter</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:168pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Monotherapy</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Combination Therapy</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:173pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Trastuzumab</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">1</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:178pt;left:207pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:189pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 105</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Trastuzumab</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">2</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:178pt;left:285pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:269pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 72</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:334pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Trastuzumab plus </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:353pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">paclitaxel</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">3</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:362pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 32</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:438pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Trastuzumab plus </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:457pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">docetaxel</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">4</span></b></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:463pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 110</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response rate</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(95 %CI)</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:175pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 % (15 - 35) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27 % (14 - 43) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:348pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59 % (41-76) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">73 % (63-81) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median duration of </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">response (months) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(range)</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10.1 (2.8-35.6) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7.9 (2.1-18.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:348pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10.5 (1.8-21) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:448pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13.4 (2.1-55.1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median TTP </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(months) (95 %CI)</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:179pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.4 (2.8-4.1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:257pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7.7 (4.2-8.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:348pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12.2 (6.2-ne) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:453pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13.6 (11-16) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median Survival</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(months) (95 %CI)</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ne </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:280pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ne </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:372pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ne </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:454pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">47.3 (32-ne) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.52pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">TTP = time to progression; &quot;ne&quot; indicates that it could not be estimated or it was not yet reached. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">1.       Study WO16229: loading dose 8 mg/kg, followed by 6 mg/kg 3 weekly schedule </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">2.       Study MO16982: loading dose 6 mg/kg weekly x 3; followed by 6 mg/kg 3-weekly schedule </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">3.       Study BO15935 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">4.       Study MO16419 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Sites of progression</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The frequency of progression in the liver was significantly reduced in patients treated with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination of trastuzumab and paclitaxel, compared to paclitaxel alone (21.8 % versus 45.7 %; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p = 0.004). More patients treated with trastuzumab and paclitaxel progressed in the central nervous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">system than those treated with paclitaxel alone (12.6 % versus 6.5 %; p = 0.377). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Early breast cancer (adjuvant setting)</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EBC is defined as non-metastatic primary invasive carcinoma of the breast. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the adjuvant treatment setting, trastuzumab was investigated in 4 large multicentre, randomised, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trials. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study BO16348 was designed to compare one and two years of three-weekly trastuzumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment versus observation in patients with HER2 positive EBC following surgery, established </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chemotherapy and radiotherapy (if applicable). In addition, comparison of two years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab treatment versus one year of trastuzumab treatment was performed. Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assigned to receive trastuzumab were given an initial loading dose of 8 mg/kg, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 mg/kg every three weeks for either one or two years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The NSABP B-31 and NCCTG N9831 studies that comprise the joint analysis were designed to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigate the clinical utility of combining trastuzumab treatment with paclitaxel following AC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chemotherapy; additionally, the NCCTG N9831 study also investigated adding trastuzumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sequentially to AC&#x2192;P chemotherapy in patients with HER2 positive EBC following surgery. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The BCIRG 006 study was designed to investigate combining trastuzumab treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">docetaxel either following AC chemotherapy or in combination with docetaxel and carboplatin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with HER2 positive EBC following surgery. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">22 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EBC in the HERA trial was limited to operable, primary, invasive adenocarcinoma of the breast, with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">axillary nodes positive or axillary nodes negative if tumours at least 1 cm in diameter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the joint analysis of the NSABP B-31 and NCCTG N9831 studies, EBC was limited to women with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">operable breast cancer at high risk, defined as HER2-positive and axillary lymph node positive or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HER2 positive and lymph node negative with high risk features (tumour size &gt; 1 cm and ER negative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or tumour size &gt; 2 cm, regardless of hormonal status). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the BCIRG 006 study HER2 positive, EBC was defined as either lymph node positive or high risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">node negative patients with no (pN0) lymph node involvement, and at least 1 of the following factors: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tumour size greater than 2 cm, estrogen receptor and progesterone receptor negative, histological </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and/or nuclear grade 2-3, or age &lt; 35 years). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy results from the BO16348 trial following 12 months* and 8 years** median follow-up </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are summarized in Table 6: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 6 Efficacy results from study BO16348 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:268pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median follow-up </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">12 months* </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:424pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median follow-up </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:444pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8 years** </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Parameter </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:242pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Observation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:250pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 1693 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:317pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Trastuzumab </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:333pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1 Year </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:328pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 1693 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:398pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Observation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:398pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 1697*** </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:473pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Trastuzumab </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:489pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1 Year </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:476pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 1702*** </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease-free survival </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">- No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">- No. patients without event  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">P-value versus Observation  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hazard Ratio versus Observation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:310pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:244pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">219 (12.9 %)        127 (7.5 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1474 (87.1 %)     1566 (92.5 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:300pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.54 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:398pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">570 (33.6 %)       471 (27.7 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1127 (66.4 %)     1231 (72.3 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:446pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:456pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.76 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Recurrence-free survival </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">- No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">- No. patients without event  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">P-value versus Observation  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hazard Ratio versus Observation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:310pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:244pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">208 (12.3 %)        113 (6.7 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1485 (87.7 %)     1580 (93.3 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:300pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.51 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:398pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">506 (29.8 %)       399 (23.4 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1191 (70.2 %)     1303 (76.6 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:446pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:456pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.73 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Distant disease-free survival </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">- No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">- No. patients without event  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">P-value versus Observation  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hazard Ratio versus Observation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:310pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:245pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">184 (10.9 %)         99 (5.8 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1508 (89.1 %)     1594 (94.6 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:300pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:398pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">488 (28.8 %)       399 (23.4 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1209 (71.2 %)     1303 (76.6 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:446pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:456pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.76 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Overall survival (death) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">- No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">- No. patients without event  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">P-value versus Observation  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hazard Ratio versus Observation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:310pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:248pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 (2.4 %)           31 (1.8 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1653 (97.6 %)     1662 (98.2 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:300pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:300pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:466pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:398pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">350 (20.6 %)       278 (16.3 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1347 (79.4 %)     1424 (83.7 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0005 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:456pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.76 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">*Co-primary endpoint of DFS of 1 year versus observation met the pre-defined statistical boundary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">**Final analysis (including crossover of 52 % of patients from the observation arm to trastuzumab) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">*** There is a discrepancy in the overall sample size due to a small number of patients who were randomised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">after the cut-off date for the 12-month median follow-up analysis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy results from the interim efficacy analysis crossed the protocol pre-specified statistical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">boundary for the comparison of 1-year of trastuzumab versus observation. After a median follow-up of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months, the hazard ratio (HR) for disease free survival (DFS) was 0.54 (95 % CI 0.44, 0.67) which </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">23 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">translates into an absolute benefit, in terms of a 2-year disease-free survival rate, of 7.6 percentage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">points (85.8 % versus 78.2 %) in favour of the trastuzumab arm. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A final analysis was performed after a median follow-up of 8 years, which showed that 1 year </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab treatment is associated with a 24 % risk reduction compared to observation only </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(HR = 0.76, 95 % CI 0.67, 0.86). This translates into an absolute benefit in terms of an 8 year disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">free survival rate of 6.4 percentage points in favour of 1 year trastuzumab treatment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In this final analysis, extending trastuzumab treatment for a duration of two years did not show </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additional benefit over treatment for 1 year [DFS HR in the intent to treat (ITT) population of 2 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">versus 1 yea r= 0.99 (95 % CI: 0.87, 1.13), p-value = 0.90 and OS HR = 0.98 (0.83, 1.15); p-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">value = 0.78]. The rate of asymptomatic cardiac dysfunction was increased in the 2-year treatment arm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(8.1 % versus 4.6 % in the 1-year treatment arm). More patients experienced at least one grade 3 or 4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adverse event in the 2-year treatment arm (20.4 %) compared with the 1-year treatment arm (16.3 %). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the NSABP B-31 and NCCTG N9831 studies trastuzumab was administered in combination with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paclitaxel, following AC chemotherapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Doxorubicin and cyclophosphamide were administered concurrently as follows: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intravenous push doxorubicin, at 60 mg/ m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, given every 3 weeks for 4 cycles. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intravenous cyclophosphamide, at 600 mg/ m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> over 30 minutes, given every 3 weeks for 4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cycles </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paclitaxel, in combination with trastuzumab, was administered as follows: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intravenous paclitaxel &#x2013; 80 mg/ m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> as a continuous intravenous infusion, given every week for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intravenous paclitaxel &#x2013; 175 mg/ m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> as a continuous intravenous infusion, given every 3 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 4 cycles (day 1 of each cycle). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy results from the joint analysis of the NSABP B-31 and NCCTG N9831 trials at the time </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the definitive analysis of DFS* are summarized in Table 7. The median duration of follow up was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8 years for the patients in the AC&#x2192;P arm and 2.0 years for patients in the AC&#x2192;PH arm. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 7 Summary of efficacy results from the joint analysis of the NSABP B-31 and NCCTG N9831 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trials at the time of the definitive DFS analysis* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:119pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Parameter </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:239pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC&#x2192;P </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:232pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(n = 1679) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:316pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC&#x2192;PH </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:314pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(n = 1672) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:391pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Hazard Ratio vs </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:412pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC&#x2192;P  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(95% CI)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:412pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease-free survival </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No. patients with event (%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Distant Recurrence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Death (OS event): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:232pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">261 (15.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:232pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">193 (11.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:238pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">92 (5.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:317pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">133 (8.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">96 (5.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62 (3.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:393pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.48 (0.39, 0.59) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:406pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:393pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.47 (0.37, 0.60) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:406pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:429pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:393pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.67 (0.48, 0.92) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:403pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p = 0.014** </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">A: doxorubicin; C: cyclophosphamide; P: paclitaxel; H: trastuzumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">* At median duration of follow up of 1.8 years for the patients in the AC&#x2192;P arm and 2.0 years for patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">AC&#x2192;PH arm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">** p value for OS did not cross the pre-specified statistical boundary for comparison of AC&#x2192;PH vs. AC&#x2192;P </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the primary endpoint, DFS, the addition of trastuzumab to paclitaxel chemotherapy resulted in a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 % decrease in the risk of disease recurrence. The hazard ratio translates into an absolute benefit, in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">terms of 3-year disease-free survival rate estimates of 11.8 percentage points (87.2 % versus 75.4 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in favour of the AC&#x2192;PH (trastuzumab) arm. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At the time of a safety update after a median of 3.5-3.8 years follow up, an analysis of DFS reconfirms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the magnitude of the benefit shown in the definitive analysis of DFS. Despite the cross-over to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab in the control arm, the addition of trastuzumab to paclitaxel chemotherapy resulted in a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 % decrease in the risk of disease recurrence. The addition of trastuzumab to paclitaxel </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chemotherapy also resulted in a 37 % decrease in the risk of death. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The pre-planned final analysis of OS from the joint analysis of studies NSABP B-31 and NCCTG </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N9831 was performed when 707 deaths had occurred (median follow-up 8.3 years in the AC&#x2192;P H </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">group). Treatment with AC&#x2192;PH resulted in a statistically significant improvement in OS compared </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with AC&#x2192;P (stratified HR = 0.64; 95% CI [0.55, 0.74]; log-rank p-value &lt; 0.0001). At 8 years, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">survival rate was estimated to be 86.9 % in the AC&#x2192;PH arm and 79.4 % in the AC&#x2192;P arm, an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">absolute benefit of 7.4 % (95 % CI 4.9 %, 10.0 %). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The final OS results from the joint analysis of studies NSABP B-31 and NCCTG N9831 are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">summarized in Table 8 below: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 8 Final overall survival analysis from the joint analysis of trials NSABP B-31 and NCCTG </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N9831 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Parameter </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:238pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC&#x2192;P </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:230pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 2032) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:316pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC&#x2192;PH </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:312pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(N = 2031) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:388pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value versus </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:405pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC&#x2192;P </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:465pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Hazard Ratio </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:463pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">versus AC&#x2192;P </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:473pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(95 % CI) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Death (OS event): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No. patients with event (%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:255pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">418 (20.6 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">289 (14.2 %) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:421pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:402pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:497pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:487pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.64  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(0.55, 0.74) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">A: doxorubicin; C: cyclophosphamide; P: paclitaxel; H: trastuzumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DFS analysis was also performed at the final analysis of OS from the joint analysis of studies NSABP </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">B-31 and NCCTG N9831. The updated DFS analysis results (stratified HR = 0.61; 95% CI [0.54, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.69]) showed a similar DFS benefit compared to the definitive primary DFS analysis, despite 24.8 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients in the AC&#x2192;P arm who crossed over to receive trastuzumab. At 8 years, the disease-free </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">survival rate was estimated to be 77.2 % (95 % CI: 75.4, 79.1) in the AC&#x2192;PH arm, an absolute benefit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of 11.8% compared with the AC&#x2192;P arm. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the BCIRG 006 study trastuzumab was administered either in combination with docetaxel, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following AC chemotherapy (AC&#x2192;DH) or in combination with docetaxel and carboplatin (DCarbH). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Docetaxel was administered as follows: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intravenous docetaxel &#x2013; 100 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> as an intravenous infusion over 1 hour, given every 3 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 4 cycles (day 2 of first docetaxel cycle, then day 1 of each subsequent cycle). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intravenous docetaxel &#x2013; 75 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> as an intravenous infusion over 1 hour, given every 3 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 6 cycles (day 2 of cycle 1, then day 1 of each subsequent cycle). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which was followed by: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carboplatin &#x2013; at target AUC = 6 mg/mL/min administered by intravenous infusion over 30-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 minutes repeated every 3 weeks for a total of six cycles. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab was administered weekly with chemotherapy and 3 weekly thereafter for a total of 52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">25 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy results from the BCIRG 006 are summarized in Tables 9 and 10. The median duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">follow up was 2.9 years in the AC&#x2192;D arm and 3.0 years in each of the AC&#x2192;DH and DCarbH arms. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 9 Overview of efficacy analyses BCIRG 006 AC</span><tt><span style="font-family:MS Mincho,monospace;font-size:11.04pt">&#x2192;</span></tt><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">D versus AC</span><tt><span style="font-family:MS Mincho,monospace;font-size:11.04pt">&#x2192;</span></tt><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DH </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Parameter </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:230pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC</span></b><tt><span style="font-family:MS Mincho,monospace;font-size:11.04pt">&#x2192;</span></tt><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">D </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:223pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(n = 1073) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:323pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC</span></b><tt><span style="font-family:MS Mincho,monospace;font-size:11.04pt">&#x2192;</span></tt><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DH </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:321pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(n = 1074) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:408pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Hazard Ratio vs </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:429pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC</span></b><tt><span style="font-family:MS Mincho,monospace;font-size:11.04pt">&#x2192;</span></tt><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">D </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:423pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(95 % CI) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:429pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease-free survival </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:239pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">195 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">134 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.61 (0.49, 0.77) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:423pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Distant recurrence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:239pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">144 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">95 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.59 (0.46, 0.77) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:423pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Death (OS event) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:241pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.58 (0.40, 0.83) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:423pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p = 0.0024 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">AC&#x2192;D = doxorubicin plus cyclophosphamide, followed by docetaxel; AC&#x2192;DH = doxorubicin plus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">cyclophosphamide, followed by docetaxel plus trastuzumab; CI = confidence interval </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 10 Overview of efficacy analyses BCIRG 006 AC</span><tt><span style="font-family:MS Mincho,monospace;font-size:11.04pt">&#x2192;</span></tt><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">D versus DCarbH </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Parameter </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:234pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC</span></b><tt><span style="font-family:MS Mincho,monospace;font-size:11.04pt">&#x2192;</span></tt><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">D </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:228pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(n = 1073) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:329pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DCarbH </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:326pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(n = 1074) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:408pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Hazard Ratio vs </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:429pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC</span></b><tt><span style="font-family:MS Mincho,monospace;font-size:11.04pt">&#x2192;</span></tt><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">D </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:423pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(95 % CI) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:429pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease-free survival </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:243pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">195 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">145 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.67 (0.54, 0.83) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:423pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p = 0.0003 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Distant recurrence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:243pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">144 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">103 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.65 (0.50, 0.84) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:423pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p = 0.0008 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Death (OS event) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:246pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:344pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.66 (0.47, 0.93) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:423pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p = 0.0182 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">AC</span><tt><span style="font-family:MS Mincho,monospace;font-size:11.04pt">&#x2192;</span></tt><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">D = doxorubicin plus cyclophosphamide, followed by docetaxel; DCarbH = docetaxel, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carboplatin and trastuzumab; CI = confidence interval </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the BCIRG 006 study for the primary endpoint, DFS, the hazard ratio translates into an absolute </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benefit, in terms of 3-year disease-free survival rate estimates of 5.8 percentage points (86.7 % versus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80.9 %) in favour of the AC</span><tt><span style="font-family:MS Mincho,monospace;font-size:11.04pt">&#x2192;</span></tt><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DH (trastuzumab) arm and 4.6 percentage points (85.5 % versus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80.9 %) in favour of the DCarbH (trastuzumab) arm compared to AC</span><tt><span style="font-family:MS Mincho,monospace;font-size:11.04pt">&#x2192;</span></tt><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">D. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study BCIRG 006, 213/1075 patients in the DCarbH (TCH) arm, 221/1074 patients in the AC</span><span style="font-family:SimSun,serif;font-size:11.04pt">&#x2192;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DH </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(AC</span><span style="font-family:SimSun,serif;font-size:11.04pt">&#x2192;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TH) arm, and 217/1073 in the AC</span><span style="font-family:SimSun,serif;font-size:11.04pt">&#x2192;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">D (AC</span><span style="font-family:SimSun,serif;font-size:11.04pt">&#x2192;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">T) arm had a Karnofsky performance status &#x2264; 90 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(either 80 or 90). No disease-free survival (DFS) benefit was noticed in this subgroup of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(hazard ratio = 1.16, 95 % CI [0.73, 1.83] for DCarbH (TCH) versus AC</span><span style="font-family:SimSun,serif;font-size:11.04pt">&#x2192;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">D (AC</span><span style="font-family:SimSun,serif;font-size:11.04pt">&#x2192;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">T); hazard ratio </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.97, 95 % CI [0.60, 1.55] for AC</span><span style="font-family:SimSun,serif;font-size:11.04pt">&#x2192;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DH (AC</span><span style="font-family:SimSun,serif;font-size:11.04pt">&#x2192;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TH) versus AC</span><span style="font-family:SimSun,serif;font-size:11.04pt">&#x2192;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">D). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In addition, a post-hoc exploratory analysis was performed on the data sets from the joint analysis (JA) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NSABP B-31/NCCTG N9831* and BCIRG006 clinical studies combining DFS events and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptomatic cardiac events and summarised in Table 11: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">26 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 11 Post-Hoc exploratory analysis results from the joint analysis NSABP B-31/NCCTG N9831 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and BCIRG006 clinical studies combining DFS events and symptomatic cardiac events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:251pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC&#x2192;PH  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:244pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(vs. AC&#x2192;P)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:229pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(NSABP B-31 and </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:231pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NCCTG N9831)* </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:355pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AC&#x2192;DH  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:348pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(vs. AC&#x2192;D)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:346pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(BCIRG 006) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:462pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DCarbH </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:454pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(vs. AC&#x2192;D)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:451pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(BCIRG 006) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Primary efficacy analysis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DFS Hazard ratios </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95 % CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:262pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.48  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:246pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(0.39, 0.59) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:247pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:368pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.61 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:352pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(0.49, 0.77) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:352pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.67  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:457pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(0.54, 0.83)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:459pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p = 0.0003 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Long term follow-up efficacy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">analysis** </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DFS Hazard ratios </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95 % CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:262pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.61 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:246pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(0.54, 0.69) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:248pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:368pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.72 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:352pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(0.61, 0.85) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:354pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.77 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:457pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(0.65, 0.90) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:459pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p = 0.0011 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Post-hoc exploratory analysis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with DFS and symptomatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cardiac events  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Long term follow-up** </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hazard ratios </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95 % CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:262pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.67  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:246pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(0.60, 0.75) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:368pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.77 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:352pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(0.66, 0.90) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.77  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:457pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(0.66, 0.90) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">A: doxorubicin; C: cyclophosphamide; P: paclitaxel; D: docetaxel; Carb: carboplatin; H: trastuzumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">CI = confidence interval </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">* At the time of the definitive analysis of DFS. Median duration of follow up was 1.8 years in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">AC&#x2192;P arm and 2.0 years in the AC&#x2192;PH arm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">** Median duration of long term follow-up for the Joint Analysis clinical studies was 8.3 years (range: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1 to 12.1) for the AC&#x2192;PH arm and 7.9 years (range: 0.0 to 12.2) for the AC&#x2192;P arm; Median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">duration of long term follow-up for the BCIRG 006 study was 10.3 years in both the AC&#x2192;D arm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(range: 0.0 to 12.6) arm and the DCarbH arm (range: 0.0 to 13.1), and was 10.4 years (range: 0.0 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12.7) in the AC&#x2192;DH arm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Early breast cancer (neoadjuvant-adjuvant setting)</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">So far, no results are available which compare the efficacy of trastuzumab administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chemotherapy in the adjuvant setting with that obtained in the neo-adjuvant/adjuvant setting. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:547pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the neoadjuvant-adjuvant treatment setting, study MO16432, a multicentre randomised trial, was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">designed to investigate the clinical efficacy of concurrent administration of trastuzumab with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neoadjuvant chemotherapy including both an anthracycline and a taxane, followed by adjuvant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab, up to a total treatment duration of 1 year. The study recruited patients with newly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diagnosed locally advanced (Stage III) or inflammatory EBC. Patients with HER2+ tumours were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to receive either neoadjuvant chemotherapy concurrently with neoadjuvant-adjuvant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab, or neoadjuvant chemotherapy alone. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study MO16432, trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg maintenance every 3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks) was administered concurrently with 10 cycles of neoadjuvant chemotherapy as follows: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Doxorubicin 60 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and paclitaxel 150 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, administered 3-weekly for 3 cycles, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which was followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paclitaxel 175 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> administered 3-weekly for 4 cycles, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:737pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which was followed by </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">27 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CMF on day 1 and 8 every 4 weeks for 3 cycles </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which was followed after surgery by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additional cycles of adjuvant trastuzumab (to complete 1 year of treatment) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy results from Study MO16432 are summarized in Table 12. The median duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">follow-up in the trastuzumab arm was 3.8 years.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 12 Efficacy results from MO16432 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Parameter </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:234pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Chemo + </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:224pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Trastuzumab </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:235pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(n = 115) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:316pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Chemo only </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:323pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(n = 116) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:437pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Event-free survival </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:256pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:256pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:344pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:344pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:408pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hazard Ratio </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95 % CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:401pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.65 (0.44, 0.96) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p = 0.0275 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total pathological complete </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response* (95 % CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:244pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:230pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(31.0, 49.6) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20.7 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:319pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(13.7, 29.2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p = 0.0014 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Overall survival </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No. patients with event </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:256pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:256pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:250pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:344pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:344pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:339pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:408pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hazard Ratio </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95 % CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:401pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.59 (0.35, 1.02) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p = 0.0555 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">* defined as absence of any invasive cancer both in the breast and axillary nodes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">An absolute benefit of 13 percentage points in favour of the trastuzumab arm was estimated in terms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of 3-year event-free survival rate (65 % versus 52 %). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Metastatic gastric cancer</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab has been investigated in one randomised, open-label phase III trial ToGA (BO18255) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination with chemotherapy versus chemotherapy alone. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Chemotherapy was administered as follows: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">capecitabine &#x2013; 1000 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> orally twice daily for 14 days every 3 weeks for 6 cycles (evening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">day 1 to morning of day 15 of each cycle) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intravenous 5-fluorouracil - 800 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">/day as a continuous intravenous infusion over 5 days, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">given every 3 weeks for 6 cycles (days 1 to 5 of each cycle) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Either of which was administered with: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cisplatin &#x2013; 80 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> every 3 weeks for 6 cycles on day 1 of each cycle. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">28 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy results from study BO18225 are summarised in Table 13: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 13 Efficacy results from BO18225 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Parameter</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:254pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">FP</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:130pt;left:242pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 290</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:301pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">FP +H  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:130pt;left:299pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 294</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:357pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HR (95 % CI)</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:448pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Overall Survival, Median months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:307pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:355pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.74 (0.60-0.91) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0046 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Progression-Free Survival, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Median months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:310pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:355pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.71 (0.59-0.85) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0002 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Time to Disease Progression, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Median months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:310pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:355pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.70 (0.58-0.85) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0003 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Overall Response Rate, % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:245pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34.5 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">47.3 % </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:352pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.70</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> (1.22, 2.38) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0017 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Duration of Response, Median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:71pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:253pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:310pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:355pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.54 (0.40-0.73) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:446pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.0001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">FP + H: Fluoropyrimidine/cisplatin + Trastuzumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">FP: Fluoropyrimidine/cisplatin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">a Odds ratio </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients were recruited to the trial who were previously untreated for HER2-positive inoperable locally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">advanced or recurrent and/or metastatic adenocarcinoma of the stomach or gastro-oesophageal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">junction not amenable to curative therapy. The primary endpoint was overall survival which was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined as the time from the date of randomisation to the date of death from any cause. At the time of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the analysis a total of 349 randomised patients had died: 182 patients (62.8 %) in the control arm and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">167 patients (56.8 %) in the treatment arm. The majority of the deaths were due to events related to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">underlying cancer. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Post-hoc subgroup analyses indicate that positive treatment effects are limited to targeting tumours </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with higher levels of HER2 protein (IHC 2+/FISH+ or IHC 3+). The median overall survival for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">high HER2 expressing group was 11.8 months versus 16 months, HR 0.65 (95 % CI 0.51-0.83) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the median progression free survival was 5.5 months versus 7.6 months, HR 0.64 (95 % CI 0.51-0.79) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for FP versus FP + H, respectively. For overall survival, the HR was 0.75 (95 % CI 0.51-1.11) in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">IHC 2+/FISH+ group and the HR was 0.58 (95 % CI 0.41-0.81) in the IHC 3+/FISH+ group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an exploratory subgroup analysis performed in the TOGA (BO18255) trial there was no apparent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benefit on overall survival with the addition of trastuzumab in patients with ECOG PS 2 at baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">[HR 0.96 (95 % CI 0.51-1.79)], non-measurable [HR 1.78 (95 % CI 0.87-3.66)] and locally advanced </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease [HR 1.20 (95 % CI 0.29-4.97)]. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The European Medicines Agency has waived the obligation to submit the results of studies with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reference medicinal product containing trastuzumab in all subsets of the paediatric population for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast and gastric cancer</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#008000"> </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 4.2 for information on paediatric use). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The pharmacokinetics of trastuzumab were evaluated in a population pharmacokinetic model analysis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using pooled data from 1,582 subjects, including patients with HER2 positive MBC, EBC, AGC or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other tumour types, and healthy volunteers, in 18 Phase I, II and III trials receiving trastuzumab IV. A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">two-compartment model with parallel linear and non-linear elimination from the central compartment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">described the trastuzumab concentration-time profile. Due to non-linear elimination, total clearance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increased with decreasing concentration. Therefore, no constant value for half-life of trastuzumab can </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">be deduced. The t</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1/2</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> decreases with decreasing concentrations within a dosing interval (see Table 16). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MBC and EBC patients had similar PK parameters (e.g. clearance (CL), the central compartment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">volume (V</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">)) and population-predicted steady-state exposures (C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">min</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and AUC). Linear clearance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was 0.136 L/day for MBC, 0.112 L/day for EBC and 0.176 L/day for AGC. The non-linear elimination </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">29 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">parameter values were 8.81 mg/day for the maximum elimination rate (V</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">) and 8.92 mcg/mL for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Michaelis-Menten constant (K</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">m</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">) for the MBC, EBC, and AGC patients. The central compartment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">volume was 2.62 L for patients with MBC and EBC and 3.63 L for patients with AGC. In the final </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">population PK model, in addition to primary tumour type, body-weight, serum aspartate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aminotransferase and albumin were identified as a statistically significant covariates affecting the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure of trastuzumab. However, the magnitude of effect of these covariates on trastuzumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure suggests that these covariates are unlikely to have a clinically meaningful effect on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab concentrations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The population predicted PK exposure values (median with 5th - 95th Percentiles) and PK parameter </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">values at clinically relevant concentrations (C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> and C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">min</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">) for MBC, EBC and AGC patients treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with the approved q1w and q3w dosing regimens are shown in Table 14 (cycle 1), Table 15 (steady- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">state), and Table 16 (PK parameters). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 14 Population predicted cycle 1 PK exposure values (median with 5th - 95th percentiles) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fortrastuzumab intravenous dosing regimens in MBC, EBC and AGC patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:85pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Regimen </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:148pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Primary tumour </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:177pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">type </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:256pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">C</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">min</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:300pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(mcg/mL) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:387pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">C</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">max</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:374pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(mcg/mL) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:455pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AUC</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">0-21days </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:447pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(mcg.day/mL) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:106pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:83pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 mg/kg + </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:77pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 mg/kg q3w </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:187pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:175pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:260pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">805 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(2.9 - 46.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:397pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">182 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(134 - 280) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:480pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:469pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1376 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:453pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(728 - 1998) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:187pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:176pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:260pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">390 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:295pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(18.7 - 45.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">176 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(127 - 227) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:469pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1390 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:450pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(1039 - 1895) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:187pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:175pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">AGC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:260pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">274 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(6.1 - 50.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">132 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:370pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(84.2 &#x2013; 225) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:469pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1109 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:452pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(588 &#x2013; 1938) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:106pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:83pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 mg/kg + </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 mg/kg qw </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:187pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:175pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:260pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">805 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(8.7 - 58.9) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">76.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:371pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(49.4 - 114) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:469pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1073 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:452pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(597 &#x2013; 1584) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:187pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:176pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:260pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">390 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:295pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(25.3 - 58.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">76.0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:371pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(54.7 - 104) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:469pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1074 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:453pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(783 - 1502) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 15 Population predicted steady state PK exposure values (median with 5th - 95th percentiles)for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab intravenous dosing regimens in MBC, EBC and AGC patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Regimen </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:174pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:154pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Primary </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:145pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">tumour type </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:235pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:231pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:295pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:280pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">C</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">min,ss*</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:272pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(mcg/mL) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:366pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:349pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">C</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">max,ss** </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:343pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(mcg/mL) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:433pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:404pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">AUC</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">ss, 0-21days</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:400pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(mcg.day/mL) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:478pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:479pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">steady- </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:477pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">state*** </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:480pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(week) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 mg/kg + </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 mg/kg q3w </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:162pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:235pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">805 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">44.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:269pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> (1.8 - 85.4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:358pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">179  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(123 - 266) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:422pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1736  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:406pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(618 - 2756) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:496pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:490pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:235pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">390 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">53.8  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:268pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(28.7 - 85.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:358pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">184  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(134 - 247) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:422pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1927  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(1332 -2771) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:496pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:490pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:162pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">AGC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:235pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">274 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32.9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:269pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(6.1 &#x2013; 88.9) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:358pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">131  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(72.5 -251) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:422pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1338  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:406pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(557 - 2875) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:496pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:493pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 mg/kg + </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:77pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 mg/kg qw </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:162pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:235pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">805 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">63.1  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:269pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(11.7 - 107) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:358pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">107 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:338pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> (54.2 - 164) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:422pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1710  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:406pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(581 - 2715) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:496pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:490pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:235pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">390 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">72.6  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(46 - 109) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:358pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">115  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:340pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(82.6 - 160) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:422pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1893  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(1309 -2734) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:496pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:490pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">*C</span><span style="font-family:TimesNewRoman,serif;font-size:6.48pt">min,ss </span><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">&#x2013; C</span><span style="font-family:TimesNewRoman,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRoman,serif;font-size:9.96pt"> at steady state </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">**C</span><span style="font-family:TimesNewRoman,serif;font-size:6.48pt">max,ss </span><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">= C</span><span style="font-family:TimesNewRoman,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRoman,serif;font-size:9.96pt"> at steady state </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:9.96pt">*** time to 90% of steady-state </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Table 16 Population predicted PK parameter values at steady state for trastuzumab intravenous dosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regimens in MBC, EBC and AGC patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:118pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:97pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Regimen </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:200pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:180pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Primary </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:171pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">tumour type </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:292pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Total CL range </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:301pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">from C</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">max,ss</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:309pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">to C</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">min,ss</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:311pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(L/day) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:442pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:387pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">t</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">1/2 </span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">range from C</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">max,ss</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">C</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">min,ss</span></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:430pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(day) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 mg/kg + </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:89pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 mg/kg q3w </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:249pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">805 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:299pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.183 - 0.302 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15.1 - 23.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:249pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">390 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:299pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.158 - 0.253 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17.5 &#x2013; 26.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">AGC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:249pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">274 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:299pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.189 - 0.337 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12.6 - 20.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 mg/kg + </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:92pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 mg/kg qw </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:249pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">805 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:299pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.213 - 0.259 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17.2 - 20.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:249pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">390 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:299pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.184 - 0.221 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:418pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19.7 - 23.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Trastuzumab washout</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Trastuzumab washout period was assessed following q1w or q3w intravenous administration using the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">population PK model. The results of these simulations indicate that at least 95 % of patients will reach </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations that are &lt; 1 mcg/mL (approximately 3 % of the population predicted C</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">min,ss, </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or about </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">97 % washout) by 7 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Circulating shed HER2-ECD</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The exploratory analyses of covariates with information in only a subset of patients suggested that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with greater shed HER2-ECD level had faster nonlinear clearance (lower Km) (P &lt; 0.001). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There was a correlation between shed antigen and SGOT/AST levels; part of the impact of shed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antigen on clearance may have been explained by SGOT/AST levels. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">31 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline levels of the shed HER2-ECD observed in MGC patients were comparable to those in MBC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and EBC patients and no apparent impact on trastuzumab clearance was observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There was no evidence of acute or multiple dose-related toxicity in studies of up to 6 months, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reproductive toxicity in teratology, female fertility or late gestational toxicity/placental transfer </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies. Trastuzumab is not genotoxic.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No long-term animal studies have been performed to establish the carcinogenic potential of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab, or to determine its effects on fertility in males. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">L-histidine hydrochloride </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">L-histidine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sorbitol (E420) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Macrogol 3350 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hydrochloric acid (for pH adjustment) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium hydroxide (for pH adjustment) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This medicinal product must not be mixed or diluted with other medicinal products except those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mentioned in section 6.6. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Glucose solutions must not be used for dilution since these cause aggregation of the protein. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After reconstitution with sterile water for injections, the reconstituted solution is physically and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chemically stable for 10 days at 2&#xb0;C &#x2013; 8&#xb0;C. Any remaining reconstituted solution should be discarded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Solutions of Ogivri for intravenous infusion are physically and chemically stable in polyvinylchloride, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyethylene or polypropylene bags containing sodium chloride 9 mg/mL (0.9 %) solution for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection for up to 90 days at 2&#xb0;C &#x2013; 8&#xb0;C and 24 hours at temperatures not exceeding 30&#xb0;C. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">From a microbiological point of view, the reconstituted solution and Ogivri infusion solution should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">be used immediately. The product is not intended to be stored after reconstitution and dilution unless </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this has taken place under controlled and validated aseptic conditions. If not used immediately, in-use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">storage times and conditions are the responsibility of the user. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Store in a refrigerator (2&#xb0;C &#x2013; 8&#xb0;C). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For storage conditions after reconstitution of the medicinal product, see sections 6.3 and 6.6. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">32 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Nature and contents of container  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri 150 mg powder for concentrate for solution for infusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 mL clear glass type I vial with butyl rubber stopper laminated with a fluoro-resin film containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">150 mg of trastuzumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each carton contains one vial. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri 420 mg powder for concentrate for solution for infusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 mL clear glass type I vial with butyl rubber stopper laminated with a fluoro-resin film containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">420 mg of trastuzumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each carton contains one vial. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for disposal and other handling </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri should be carefully handled during reconstitution. Causing excessive foaming during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reconstitution or shaking the reconstituted solution may result in problems with the amount of Ogivri </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">that can be withdrawn from the vial. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The reconstituted solution should not be frozen.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri 150 mg powder for concentrate for solution for infusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Appropriate aseptic technique should be used. Each 150 mg vial of Ogivri is reconstituted with 7.2 mL </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of sterile water for injections (not supplied). Use of other reconstitution solvents should be avoided. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This yields a 7.4 mL solution for single-dose use, containing approximately 21 mg/mL trastuzumab, at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a pH of approximately 6.0. A volume overage of 4 % ensures that the labelled dose of 150 mg can be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawn from each vial. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri 420 mg powder for concentrate for solution for infusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each 420 mg vial of Ogivri is reconstituted with 20 mL of sterile water for injections (not supplied). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Use of other reconstitution solvents should be avoided. This yields a 21 mL solution for single-dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">use, containing approximately 21 mg/mL trastuzumab, at a pH of approximately 6.0. A volume </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">overage of 4.8 % ensures that the labelled dose of 420 mg can be withdrawn from each vial. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri vial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:191pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Volume of sterile water for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:368pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Final concentration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">150 mg vial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">+ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7.2 mL </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">= </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21 mg/mL </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">420 mg vial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:188pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">+ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:211pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mL </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">= </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21 mg/mL </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Instructions for reconstitution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1) Using a sterile syringe, slowly inject the appropriate volume (as noted above) of sterile water for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injections in the vial containing the lyophilised Ogivri, directing the stream into the lyophilised cake. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2) Swirl the vial gently to aid reconstitution. DO NOT SHAKE! </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Slight foaming of the product upon reconstitution is not unusual. Allow the vial to stand undisturbed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for approximately 5 minutes. The reconstituted Ogivri results in a colourless to pale yellow transparent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">solution and should be essentially free of visible particulates. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">33 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Determine the volume of the solution required: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022;    based on a loading dose of 4 mg trastuzumab/kg body weight, or a subsequent weekly dose of 2 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trastuzumab/kg body weight: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:93pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Volume </span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(mL) = </span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Body weight </span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(kg) x </span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">dose </span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4 </span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg for loading or </span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2 </span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg for maintenance) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:183pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">21 </span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(mg/mL, concentration of reconstituted solution) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022;    based on a loading dose of 8 mg trastuzumab/kg body weight, or a subsequent 3-weekly dose of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 mg trastuzumab/kg body weight: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:93pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Volume </span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(mL) = </span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Body weight </span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(kg) x </span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">dose </span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8 </span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg for loading or </span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6 </span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg for maintenance) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:183pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">21 </span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(mg/mL, concentration of reconstituted solution) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The appropriate amount of solution should be withdrawn from the vial using a sterile needle and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">syringe and added to an infusion bag containing 250 mL of sodium chloride 9 mg/mL (0.9 %) solution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for injection. Do not use with glucose-containing solutions (see section 6.2). The bag should be gently </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inverted to mix the solution in order to avoid foaming. Once the infusion is prepared it should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered immediately. If diluted aseptically, it may be stored for up to 90 days at 2&#xb0;C &#x2013; 8&#xb0;C and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 hours at temperatures not exceeding 30&#xb0;C. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Parenteral medicinal products should be inspected visually for particulate matter and discoloration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prior to administration. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ogivri is for single-use only, as the product contains no preservatives.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No incompatibilities between Ogivri and polyvinylchloride, polyethylene or polypropylene bags have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Viatris Limited </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Damastown Industrial Park </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mulhuddart </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Dublin 15 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">DUBLIN </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ireland </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER(S)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/18/1341/001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/18/1341/002 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of first authorisation: 12 December 2018 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">34 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:77pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:221pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></p>
</div>


























</body>
</html> 

